Participated · Series B · Feb 2021

WuXi Diagnostics builds an open-access innovation enabling platform for integrated diagnostics centered on multi-omics clinical data and multidisciplinary technologies. The platform is designed to continuously launch diagnostic services and products and to empower healthcare innovators to accelerate technology translation from R&D to application. The company leverages Mayo Clinic knowledge and expertise in integrated medicine and maintains an R&D center at Mayo Clinic headquarters in Rochester, U.S. It operates a headquarters and a CAP-accredited independent clinical laboratory in Shanghai and an ISO13485-certified production facility in Suzhou. Led by CEO Dr. Jason Liu and established in 2018, WuXi Diagnostics completed a US$150M Series B to strengthen its platform, advance its integrated diagnostics R&D pipeline, and accelerate global market penetration. The company aims to build a new ecosystem for next-generation diagnostics through its open-access enabling platform.